



February 3, 2016

Mirna Therapeutics to Present at the BIO CEO & Investor and LEERINK Global Healthcare Conferences in February

AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced its participation in two healthcare investor conferences during the month of February.

Conference Details:

▮ **The 18th Annual BIO CEO & Investor Conference**

On Tuesday, February 9, 2016, President and CEO Paul Lammers, M.D., M.Sc., will present a corporate overview at 11:00 AM EST. The conference is being held at the Waldorf Astoria in New York City.

▮ **LEERINK Partners 5th Annual Global Healthcare Conference**

On Thursday, February 11, 2016, Dr. Lammers will participate in a fireside chat to discuss recent corporate developments at 3:05 PM EST. The conference is being held at the Waldorf Astoria in New York City.

The BIO CEO presentation will be webcast live and may be accessed from the [Events & Presentations](#) section of the Company's website. An archived version of the webcast will be available for replay following the event.

About Mirna Therapeutics, Inc.

Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The company was founded in 2007 and is located in Austin, Texas.

For more information, visit www.mirnarx.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160203005284/en/>

Investors

The Trout Group
Josh Barer, 646-378-2948
jbarer@troutgroup.com

or

Media

BMC Communications
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com

Source: Mirna Therapeutics, Inc.

News Provided by Acquire Media